{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000038","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-07-09T20:09:51+00:00","discovered_at":"2026-07-09T20:11:00.864208+00:00","generated_at":"2026-07-09T20:11:13.708664+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Nurix enters $2.3B Roche collaboration for bexobrutideg; Q2 net loss $89.5M","bullets":["Global collaboration with Roche for bexobrutideg: $700M upfront, up to $2.3B total; co-dev/co-commercialization in hematology, immunology, neurology.","Q2 FY2026 revenue $9.0M (down from $44.1M YoY); net loss $89.5M ($0.81/share) vs $43.5M loss prior year.","Cash, equivalents & marketable securities $443.5M as of May 31, 2026; pro-forma ~$1.14B including expected $700M Roche payment.","Bexobrutideg Phase 1a/1b CLL data: ORR 83% (Phase 1a) and 92.9% (Phase 1b Cohort 5); median PFS 22.1 months.","Enrollment continues in pivotal Phase 2 DAYBreak CLL-201; Phase 3 vs pirtobrutinib expected to start mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000038","json":"https://secwatch.observer/filing/0001549595-26-000038.json","markdown":"https://secwatch.observer/filing/0001549595-26-000038.md","text":"https://secwatch.observer/filing/0001549595-26-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/0001549595-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/nrix-20260709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T20:11:13.708664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}